Tenascin-C-Fragments for Spinal Cord Regeneration

Information

  • Research Project
  • 6337543
  • ApplicationId
    6337543
  • Core Project Number
    R43NS041685
  • Full Project Number
    1R43NS041685-01
  • Serial Number
    41685
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/2001 - 23 years ago
  • Project End Date
    2/28/2002 - 22 years ago
  • Program Officer Name
    KLEITMAN, NAOMI
  • Budget Start Date
    8/1/2001 - 23 years ago
  • Budget End Date
    2/28/2002 - 22 years ago
  • Fiscal Year
    2001
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/25/2001 - 23 years ago
Organizations

Tenascin-C-Fragments for Spinal Cord Regeneration

The goal of this project is to conduct pre-clinical tests of components of the extracellular matrix molecule tenascin-C that offer potential as therapeutics for enhancing nerve fiber regeneration. This may lead to the development of a treatment for spinal cord injury, a devastating condition for which there are no reparative treatments available. The study is based on a new understanding of how the fhA-D component of tenascinC regulates neurite outgrowth. The project will examine effects of delivering fnA-D recombinant protein, or its active peptide sequence (VFDNFVLK ) to the site of an experimental spinal cord injury. Hemisection of the dorsal thoracic (T9) spinal cord of rats will be used to examine the response of corticospinal and primary afferent nerve fibers to transection and treatment with the protein and peptide. Groups of animals will be assigned to treatment with fnA-D, VFDNFVLK, or buffer delivered intrathecally for two weeks from an implanted osmotic pump. Hind limb function will be monitored with a grid-walking test. The primary measure of treatment effect will be immunohistological analysis of axonal regeneration, using Cholera toxin injected either into the motor cortex or into the sciatic nerves. Effects on regeneration of axons will be examined qualitatively and measured quantitatively. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R43
  • Administering IC
    NS
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
    NINDS:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ACORDA THERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    HAWTHORNE
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    10532
  • Organization District
    UNITED STATES